INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 179 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2021. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,259,167 | +134.8% | 62,568 | +185.5% | 0.00% | +100.0% |
| Q2 2023 | $1,387,911 | -49.2% | 21,919 | -56.6% | 0.00% | -33.3% |
| Q1 2023 | $2,734,304 | +64.0% | 50,495 | +60.3% | 0.00% | +50.0% |
| Q4 2022 | $1,666,874 | -62.9% | 31,498 | -67.3% | 0.00% | -66.7% |
| Q3 2022 | $4,488,000 | -27.1% | 96,455 | -10.6% | 0.01% | -25.0% |
| Q2 2022 | $6,158,000 | +3.1% | 107,882 | +10.5% | 0.01% | +33.3% |
| Q1 2022 | $5,973,000 | +94.0% | 97,609 | +65.9% | 0.01% | +100.0% |
| Q4 2021 | $3,079,000 | -25.0% | 58,823 | -46.6% | 0.00% | -25.0% |
| Q3 2021 | $4,105,000 | +93.4% | 110,105 | +111.7% | 0.00% | +100.0% |
| Q2 2021 | $2,123,000 | +674.8% | 52,003 | +115.9% | 0.00% | +100.0% |
| Q4 2018 | $274,000 | – | 24,087 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |